

PUBBLICAZIONI 2019

Terziroli Beretta-Piccoli, B. , Thompson, R. , Foskett, P. , Cerny, A. , Merlo, E. , Vergani, D. , Rougemont, A. , Moix, I. , Mieli-Vergani, G. and Morris, M. (2019), **A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.** Hepatology. 2019 May 24. doi: 10.1002/hep.30783.

Terziroli Beretta-Piccoli B, Di Bartolomeo C, Deleonardi G, Grondona AG, Silvestri T, Tesei C, Melidona L, Cerny A, Mertens J, Semmo N, Semela D, Moradpour D, Mieli-Vergani G, Vergani D, Muratori L; **Swiss Hepatitis C Cohort Study. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents.** J Autoimmun. 2019 Apr 29. pii: S0896-8411(19)30186-6. doi: 10.1016/j.jaut.2019.04.019.

Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M4, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; **International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C.. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.** Clin Gastroenterol Hepatol. 2019 May 14. pii: S1542-3565(19)30523-3. doi: 10.1016/j.cgh.2019.05.013.

Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O; **Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?** Clin Infect Dis. 2019 Apr 3. pii: ciz270. doi: 10.1093/cid/ciz270.

Brezzi M, Bertisch B, Roelens M, Moradpour D, Terziroli Beretta-Piccoli B, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O, for the Swiss Hepatitis C Cohort Study. **Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.** PLoS One. 2019 Jun 24;14(6):e0218706. doi: 10.1371/journal.pone.0218706. eCollection 2019.

Bertola EA, Simonetti GD, Del Giorno R, Giannini O, Fossali EF, Meoli M, Bianchetti MG, Terziroli Beretta-Piccoli B, Milani GP. **Extrarenal Immune-Mediated Disorders Linked with Acute Poststreptococcal Glomerulonephritis: a Systematic Review.** Clin Rev Allerg Immunol (2019). <https://doi.org/10.1007/s12016-019-08761-w>.

Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling J, Adams D, Alpini G, Bañales Asurmendi J, Beuers U, Björnsson E, Bowlus CL, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley E, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner A, Tsuneyama K, Zigmund E, Gershwin ME. **The Challenges of Primary Biliary Cholangitis: What is new and what needs to be done.** J Autoimmun. 2019 in press.

Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O; **Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?** Clin Infect Dis. 2019 Apr 3. pii: ciz270. doi: 10.1093/cid/ciz270.

Cerny A, Blindenbacher R, Moriggia A. **Controlling HCV in Switzerland: running against the clock.** Swiss Med Wkly. 2019 Mar 24;149:w20005. doi: 10.4414/smw.2019.20005. eCollection 2019 Mar 11.

Efe C, Taşçılar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Terziroli Beretta-Piccoli B, Fischer J, Çalışkan AR, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Önnérhag K, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyıcı M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Wahlin S. **Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.** Am J Gastroenterol. 2019 Jun 19. DOI: 10.14309/ajg.0000000000000290.

Islam S, Piggott DA, Moriggia A; Astemborski J; Mehta SH, Thomas DL, Kirk GD. **Reducing Injection Intensity is Associated with Decreased Risk for Invasive Bacterial Infection among High Frequency Injection Drug Users.** Harm Reduct J. 2019 Jun 17;16(1):38. doi: 10.1186/s12954-019-0312-8.



Fondazione
Epatocentro Ticino

Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, Moriggia A, Müllhaupt B, Negro F, Razavi H, Semela D, Estes C. **Nonalcoholic fatty liver disease burden – Switzerland 2018–2030**. Swiss Med Wkly. 2019;149:w20152. doi: 10.4414/smw.2019.20152

Terziroli Beretta-Piccoli B, Taiana C, Mossi G, Vergani D, Mieli-Vergani G. **A patient with primary biliary cholangitis, autoimmune hepatitis and primary sclerosing cholangitis variant syndrome**. J Transl Autoimmun 2019, in press